DE60033555D1 - Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden - Google Patents

Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden

Info

Publication number
DE60033555D1
DE60033555D1 DE60033555T DE60033555T DE60033555D1 DE 60033555 D1 DE60033555 D1 DE 60033555D1 DE 60033555 T DE60033555 T DE 60033555T DE 60033555 T DE60033555 T DE 60033555T DE 60033555 D1 DE60033555 D1 DE 60033555D1
Authority
DE
Germany
Prior art keywords
breast cancer
compositions
detecting
provides
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60033555T
Other languages
English (en)
Other versions
DE60033555T2 (de
Inventor
Brynmor Watkins
Robert P Szaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matritech Inc
Original Assignee
Matritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matritech Inc filed Critical Matritech Inc
Application granted granted Critical
Publication of DE60033555D1 publication Critical patent/DE60033555D1/de
Publication of DE60033555T2 publication Critical patent/DE60033555T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
DE60033555T 1999-11-16 2000-11-16 Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden Expired - Fee Related DE60033555T2 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US16567399P 1999-11-16 1999-11-16
US165673P 1999-11-16
US17217099P 1999-12-17 1999-12-17
US172170P 1999-12-17
US17886000P 2000-01-27 2000-01-27
US178860P 2000-01-27
US20172100P 2000-05-03 2000-05-03
US201721P 2000-05-03
US09/709,947 US6936424B1 (en) 1999-11-16 2000-11-10 Materials and methods for detection and treatment of breast cancer
US709947P 2000-11-10
PCT/US2000/031483 WO2001036470A2 (en) 1999-11-16 2000-11-16 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides

Publications (2)

Publication Number Publication Date
DE60033555D1 true DE60033555D1 (de) 2007-04-05
DE60033555T2 DE60033555T2 (de) 2007-11-29

Family

ID=30449666

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60033555T Expired - Fee Related DE60033555T2 (de) 1999-11-16 2000-11-16 Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden

Country Status (9)

Country Link
US (2) US6936424B1 (de)
EP (2) EP1232177B1 (de)
JP (2) JP2003528296A (de)
AT (1) ATE354588T1 (de)
AU (2) AU1658901A (de)
CA (2) CA2390607A1 (de)
DE (1) DE60033555T2 (de)
ES (1) ES2282149T3 (de)
WO (2) WO2001036977A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936424B1 (en) * 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
AUPQ886100A0 (en) * 2000-07-19 2000-08-10 Biotron Limited Diagnostic test
CA2320549A1 (en) * 2000-09-25 2002-03-25 Eastern Virginia Medical College Biomarkers of transitional cell carcinoma of the bladder
CN1554021A (zh) * 2001-08-03 2004-12-08 新的癌标记物及其在癌症诊断中的用途
US6756586B2 (en) 2001-10-15 2004-06-29 Vanderbilt University Methods and apparatus for analyzing biological samples by mass spectrometry
DE60211744T3 (de) * 2001-12-08 2010-07-01 Micromass Uk Ltd. Massenspektrometrie-verfahren
AU2002365104A1 (en) * 2001-12-21 2003-07-15 Biovision Ag Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
CA2478036A1 (en) * 2002-03-06 2003-09-18 Johns Hopkins University Use of biomarkers to detect breast cancer
AU2002950878A0 (en) * 2002-08-20 2002-09-12 Proteome Systems Intellectual Property Pty Ltd Method for diagnosing disorders
MXPA05006382A (es) 2002-12-20 2005-10-24 Hoffmann La Roche Uso de nicotinamida n-metiltransferasa como un marcador para cancer colorrectal.
EP1895302A3 (de) 2003-04-08 2008-05-14 Colotech A/S Verfahren zum Nachweis von kolorektalem Krebs in menschlichen Proben
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20050037331A1 (en) * 2003-08-13 2005-02-17 William Galbraith Apparatuses and methods for reducing albumin in samples
GB0320648D0 (en) * 2003-09-03 2003-10-01 Randox Lab Ltd Molecular marker
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
EP1794593A2 (de) * 2004-09-21 2007-06-13 Matritech, Inc. Verfahren und zusammensetzungen zum nachweis von krebs unter verwendung von komponenten des u2-spleissosompartikels
EP1833838A2 (de) * 2004-12-14 2007-09-19 Applera Corporation, Applied Biosystems Group Kationische liposomen enthaltend eine ladungsneutrale verbindung und ein kationisches phospholipid
JP2008527351A (ja) 2005-01-06 2008-07-24 イースタン バージニア メディカル スクール 前立腺癌のバイオマーカーとしてのアポリポタンパク質ａ−ｉｉアイソフォーム
JP5200246B2 (ja) * 2005-03-14 2013-06-05 財団法人ヒューマンサイエンス振興財団 膵臓癌診断用マーカータンパク質
US7749445B2 (en) 2005-05-02 2010-07-06 Bioscale, Inc. Method and apparatus for analyzing bioprocess fluids
US7648844B2 (en) 2005-05-02 2010-01-19 Bioscale, Inc. Method and apparatus for detection of analyte using an acoustic device
EP1896855A2 (de) * 2005-06-21 2008-03-12 Jean-Paul Borg Serumbiomarker für brustkrebs
WO2007035766A2 (en) * 2005-09-19 2007-03-29 The Johns Hopkins University Biomarker for prostate cancer
CA2625781C (en) * 2005-10-13 2014-09-02 Applera Corporation Methods for the development of a biomolecule assay
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US20100160275A1 (en) * 2006-09-26 2010-06-24 Lee Eva Y H P Methods and compositions for cancer prevention and treatment
US8354280B2 (en) 2007-09-06 2013-01-15 Bioscale, Inc. Reusable detection surfaces and methods of using same
US20090170132A1 (en) * 2007-12-11 2009-07-02 Pevsner Paul H Methods for detecting colon carcinoma
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US8232073B2 (en) * 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
US8809009B2 (en) 2009-01-02 2014-08-19 Biomarin Pharmaceutical Inc. Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
JP2013502201A (ja) * 2009-08-21 2013-01-24 オンコセラピー・サイエンス株式会社 肺癌の治療および診断の標的遺伝子としてのｃｓｔｆ２
AU2012261953A1 (en) 2011-06-03 2013-12-12 University Of South Alabama Methods and compositions for detecting endometrial or ovarian cancer
US20170367584A1 (en) * 2015-02-11 2017-12-28 Abbott Diabetes Care Inc. Methods, Devices and Systems for Distinguishing Cancerous and Non-Cancerous Tissue
EP3387430A4 (de) * 2015-12-11 2019-08-14 Expression Pathology, Inc. Srm/mrm-tests
WO2018201078A1 (en) * 2017-04-28 2018-11-01 Masimo Corporation Spot check measurement system
CN107677825B (zh) * 2017-10-06 2019-04-23 汉氏联合（天津）干细胞研究院有限公司 一种用于宫颈癌诊断的肿瘤诊断组合物和用于制备诊断试剂盒的用途
KR20220078560A (ko) 2019-08-05 2022-06-10 시어 인코퍼레이티드 샘플 제조, 데이터 생성, 및 단백질 코로나 분석을 위한 시스템 및 방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264550A (en) 1985-04-15 1993-11-23 Scios Nova Inc. Human anti-inflammatory phospholipase inhibitor protein
US5561222A (en) 1989-11-15 1996-10-01 Duke University RNA-binding proteins useful for the control of cellular genetic processing and expression
EP0460607A3 (en) 1990-06-05 1992-04-01 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors
US5792664A (en) 1992-05-29 1998-08-11 The Rockefeller University Methods for producing and analyzing biopolymer ladders
AU676582B2 (en) 1993-05-28 1997-03-13 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
US5869286A (en) 1995-03-23 1999-02-09 Immunex Corporation Receptor that binds IL-17
US5876937A (en) 1995-07-03 1999-03-02 Akzo Nobel N.V. Method for determining the integrity of nucleic acid
US5962242A (en) 1995-09-19 1999-10-05 Immuna Care Corporation Methods of predicting estrogen-dependent osteopenia
CZ294729B6 (cs) 1996-08-13 2005-03-16 Biovision Ag Způsob in vitro zjišťování stavu organismu stanovením peptidů
DE19632521A1 (de) 1996-08-13 1998-02-19 Forssmann Wolf Georg Verfahren zur Gewinnung von Peptiden aus Köperflüssigkeiten und Geweben sowie Zellüberständen und zur Identifikation von krankheitsrelevanten Peptidmarkern
US5798266A (en) 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US7008778B1 (en) * 1997-02-03 2006-03-07 Human Genome Sciences, Inc. Breast cancer specific gene 1
JP2001523096A (ja) 1997-03-21 2001-11-20 エム ユー エス シー ファンデーション フォーリサーチ ディベロップメント 乳癌の診断および治療のための方法ならびに組成物
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
WO1999039204A1 (en) 1998-02-02 1999-08-05 Novadx Removal of abundant interfering proteins from a liquid sample using a collapsible affinity matrix
US6410692B2 (en) 1998-02-02 2002-06-25 Novadx, Inc. Removal of abundant interfering proteins from a liquid sample using a collapsible affinity matrix
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6753314B1 (en) * 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
US6936424B1 (en) 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
EP1794593A2 (de) * 2004-09-21 2007-06-13 Matritech, Inc. Verfahren und zusammensetzungen zum nachweis von krebs unter verwendung von komponenten des u2-spleissosompartikels

Also Published As

Publication number Publication date
WO2001036977A3 (en) 2001-11-22
AU1658901A (en) 2001-05-30
AU1615201A (en) 2001-05-30
DE60033555T2 (de) 2007-11-29
CA2391212A1 (en) 2001-05-25
WO2001036977A8 (en) 2002-01-24
US20060160154A1 (en) 2006-07-20
WO2001036470A2 (en) 2001-05-25
JP2003528296A (ja) 2003-09-24
ATE354588T1 (de) 2007-03-15
EP1232177B1 (de) 2007-02-21
US6936424B1 (en) 2005-08-30
CA2390607A1 (en) 2001-05-25
ES2282149T3 (es) 2007-10-16
EP1240521A2 (de) 2002-09-18
WO2001036977A2 (en) 2001-05-25
WO2001036470A3 (en) 2002-01-24
EP1232177A2 (de) 2002-08-21
JP2004500056A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
DE60033555D1 (de) Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden
ATE332505T1 (de) Verfahren und zusammensetzung zur auffindung von cervix-krebs
ATE437369T1 (de) Enzymkatalysierte metalldeposition zum verstärkten in-situ-nachweis von immunhistologischen epitopen und nukleinsäuresequenzen
DE69807878T2 (de) Erkennung und Modulierung von IAPS und NAIP zur Diagnose und Behandlung von proliferativen Erkrankungen
ATE431853T1 (de) Auf oligonukleotid-modifizierten partikeln basierende bio-strichcodes
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
DE69942451D1 (de) Methode zum schnellen identifizieren von kleinen organischen liganden
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
DK0757723T3 (da) Genetiske ændringer, der korrelerer med lungecarcinoma
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
ATE364089T1 (de) Reagenzien und methoden zum nachweis von erkrankungen der brust
WO1995016919A3 (en) Methods and compositions for the detection of colon cancers
WO2006034278A3 (en) Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
ATE325203T1 (de) Nachweis und identifikation von bakteriengruppen
WO2003033731A3 (en) Methods for detecting ovarian cancer
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
ATE487792T1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
FI973561A (fi) Menetelmä ja yhdisteitä analysoitavien aineiden määrittämiseksi remanenssimittausten avulla ja mainittujen yhdisteiden käyttö
ATE233405T1 (de) Verfahren zur detektierung eines biologischen materials, eingangphase, detektionsphase und diese enthaltende reagenz
DE60010323D1 (de) Fluoreszenzkorrelationsspektroskopie zur identifizierung von verbindung-ziel-bindung
WO2002078636A3 (en) Detection and treatment of colorectal cancer
WO2002075314A3 (en) Detection and treatment of prostate cancer
ATE353544T1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
DE69739653D1 (de) Reagentia und verfahren zum nachweis von brustkrankheiten
SE0201392D0 (sv) Fusion polypeptide, use thereof and methods employing it

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MATRITECH, INC. (N.D.GES.D. STAATES DELAWARE),, US

8339 Ceased/non-payment of the annual fee